A recent study in pancreatic cancer lines, however, suggested that NADase CD38 but not SIRT1 is crucial for pancreatic cancer cells' response to NAMPT inhibition34, suggesting the complex interaction of NAMPT with SIRT1. These previous findings, together with N39 signature, have generated novel biomarkers or therapeutic targets in cancer. This evidence concerns the gene CD38 and pancreatic neoplasm.